ArticleBioNanoScience2026
Innovative AC Electrospinning and Characterization of Nanofibers Comprised of Polyvinyl Alcohol and Dacarbazine for Solid State Drug Delivery of Cancer Therapeutic.
Article in BioNanoScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dacarbazine (DTIC) is an alkylating chemotherapeutic agent with demonstrated anti-tumor activity but limited utility for intracranial applications due to its chemical instability, short systemic half-life, and inability to cross the blood-brain barrier. Strategies that stabilize DTIC in the solid form for localized delivery therefore are of significant interest due to the material challenges. In this study, nanofibers with various polyvinyl alcohol (PVA)-to-dacarbazine ratios ranging from 2.5:1, 5:1, 7.5:1, to 10:1 were developed using alternating-current electrospinning (ACES) at an extremely high production rate. Their structural and physiochemical properties were systematically characterized to assess the feasibility of this approach using different characterization methods such as X-ray diffraction (XRD), Fourier-transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Additionally, the encapsulation efficiency (EE) and the drug release profile was evaluated using Ultraviolet-visible spectroscopy (UV-Vis). The characterization results show that nanofibers obtained using the ACES approach have good DTIC dispersion in the PVA matrix and the DTIC remains individualistic in the nanofiber. These results collectively demonstrate that ACES enables the incorporation of dacarbazine into PVA nanofibers while preserving favorable fiber morphology and promoting solid-state stabilization. This work shows the novelty in the application of ACES to fabricate dacarbazine-loaded PVA nanofibers with controlled morphology and solid-state drug stabilization. It also establishes a foundational materials platform for localized dacarbazine delivery and providing a basis for future studies focused on drug release behavior, stability, and therapeutic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.